Phase 1 Study of the Safety, Pharmacokinetics, and Antitumour Activity of the BCL2 Inhibitor Navitoclax in Combination With Rituximab in Patients With Relapsed or Refractory CD20+ Lymphoid Malignancies

The oral BCL2 inhibitor navitoclax has moderate single-agent efficacy in chronic lymphocytic leukaemia (CLL) and minor activity in lymphoma in Phase 1 trials. Navitoclax synergizes with rituximab in preclinical models of B-cell lymphoid cancers. We report the safety, pharmacokinetics, and clinical a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Br J Haematol
Autores principales: Roberts, Andrew W., Advani, Ranjana H., Kahl, Brad, Persky, Daniel, Sweetenham, John W., Carney, Dennis A., Yang, Jianning, Busman, Todd B., Enschede, Sari H., Humerickhouse, Roderick A., Seymour, John F.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4534314/
https://ncbi.nlm.nih.gov/pubmed/25942994
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13487
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares